Alector, Inc.
ALEC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001653087
In the last 90 days, Alector, Inc. insiders filed 0 open-market purchases and 3 sales; 140 institutions reported holding it in 13F filings for Q2 2026, worth $183.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:55 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $142.9M (679.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Jan 16, 2024 | Feb 28, 2023 | Feb 24, 2022 |
| Revenue | $21.0M | $100.6M | $97.1M | $133.6M | $207.1M |
| Operating expenses | $177.1M | $245.6M | $248.8M | $271.5M | $244.4M |
| Research and development | $123.1M | $185.9M | $192.1M | $210.4M | $189.4M |
| Selling, general and administrative | $54.0M | $59.6M | $56.7M | $61.0M | $55.0M |
| Operating income | -$156.0M | -$145.0M | -$151.7M | -$137.8M | -$37.4M |
| Income tax | $168.0K | $128.0K | $5.21M | $3.25M | $0 |
| Net income | -$142.9M | -$119.0M | -$130.4M | -$133.3M | -$36.3M |
| EPS, basic | $-1.39 | $-1.23 | $-1.56 | $-1.62 | – |
| EPS, diluted | $-1.39 | $-1.23 | $-1.56 | $-1.62 | – |
| Weighted shares, basic | 103.0M | 96.6M | 83.7M | 82.5M | – |
| Weighted shares, diluted | 103.0M | 96.6M | 83.7M | 82.5M | – |
| Margins and growth | |||||
| Operating margin | -741.3% | -144.1% | -156.3% | -103.2% | -18.0% |
| Net margin | -679.2% | -118.3% | -134.3% | -99.8% | -17.5% |
| Revenue growth, year over year | −79.1% | +3.6% | −27.4% | −35.5% | +881.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Jan 16, 2024 | Feb 28, 2023 | Feb 24, 2022 |
| Cash and equivalents | $65.8M | $33.0M | $74.6M | $154.3M | $329.2M |
| Short-term investments | $190.2M | $380.4M | $474.3M | $558.5M | $406.1M |
| Total current assets | $266.5M | $424.8M | $565.8M | $726.4M | $749.7M |
| Property, plant and equipment | $10.8M | $17.1M | $21.9M | $25.5M | $27.3M |
| Total assets | $293.2M | $468.3M | $621.8M | $787.6M | $814.7M |
| Accounts payable | $1.69M | $2.21M | $3.77M | $4.19M | $4.75M |
| Short-term debt | $366.0K | – | – | – | – |
| Total current liabilities | $69.5M | $125.1M | $177.9M | $93.8M | $139.6M |
| Long-term debt | $9.32M | $9.39M | – | – | – |
| Total liabilities | $262.6M | $341.5M | $487.7M | $573.2M | $513.9M |
| Shareholders' equity | $30.6M | $126.8M | $134.2M | $214.4M | $300.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Jan 16, 2024 | Feb 28, 2023 | Feb 24, 2022 |
| Operating cash flow | -$184.0M | -$229.9M | -$184.2M | -$20.3M | $298.6M |
| Capital expenditures | $41.0K | $1.25M | $2.38M | $4.12M | $3.25M |
| Free cash flow | -$184.1M | -$231.2M | -$186.5M | -$24.4M | $295.3M |
| Depreciation and amortization | $5.72M | $5.41M | $5.72M | $5.71M | $6.33M |
| Stock-based compensation | $26.7M | $39.5M | $42.8M | $46.1M | $40.8M |
| Investing cash flow | $196.6M | $107.1M | $101.9M | -$159.0M | -$49.7M |
| Financing cash flow | $20.2M | $81.5M | $2.55M | $4.51M | $30.3M |
| Net change in cash | $32.8M | -$41.2M | -$79.7M | -$174.8M | $279.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 126.7% | 39.2% | 44.1% | 34.5% | 19.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 148.9M | +36.4% | SEC |
| Jul 31, 2026 | 111.7M | +10.3% | SEC |
| May 1, 2026 | 111.0M | +11.0% | SEC |
| Feb 20, 2026 | 110.4M | +11.4% | SEC |
| Oct 31, 2025 | 109.2M | +11.5% | SEC |
| Aug 1, 2025 | 101.2M | +4.0% | SEC |
| May 2, 2025 | 100.0M | +3.7% | SEC |
| Feb 21, 2025 | 99.1M | +3.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.